Promore Pharma
9.11.2021 12:02:15 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
Stockholm, November 9, 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced today that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.
The company announces today that a clinical trial permit has been obtained from the Medical Products Agency in Sweden and that the company's application for approval from the Ethical Review Authority has also been granted. PHSU05 is a Phase II pilot study with the aim of being able to evaluate ensereptide regarding (i) local tolerance, (ii) the application process of the experimental drug, and (iii) preliminary effect on scar prevention after experimentally induced wounds in healthy volunteers. Planned study start is Q1 2022 and results from the study are expected in the winter of 2022/2023.
"This is an important step in our long-term goal of developing a new product concept to prevent the occurrence of post-surgical and post-traumatic scars on the skin. These approvals are fully aligned with our operational plan in the ensereptide project ", says Jonas Ekblom, CEO of Promore Pharma.
Bolagets ensereptide-program fokuseras för närvarande på prevention av ärr i huden i samband med kirurgi eller trauma, men det finns även potential att utveckla produkten för andra medicinska applikationer som prevention av sammanväxning efter hand- och ryggradskirurgi.
The company's ensereptide program is currently focused on the prevention of scarring of the skin in connection with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of adhesions after surgeries in the hand or spine.
Scars develop after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically pleasing, and they can also create itching, stiffness, sleep problems, anxiety, depression and negatively affect activities of daily life.
The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, amounts to USD 25 billion with an annual growth of about 10%, according to independent estimates. Today, there are no prescription drugs for wound prevention.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
This information is information that Promore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-09 11:38 CET.
Attachments
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/671849/Promore-Pharma-Receives-Permits-to-Start-a-Phase-II-Clinical-Trial-Regarding-Scar-Prevention
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Innodata Releases the First Stage of Its AI Cyber Training Suite to Enable AI Coding Agents to Write - and Repair - Secure Code4.8.2026 14:30:00 CEST | Press release
Twelve datasets and evaluation systems, built by hand from thousands of real-world security flaws, give model builders and enterprises a proven way to keep AI-generated code from introducing vulnerabilities. NEW YORK, NY / ACCESS Newswire / August 4, 2026 / INNODATA INC. (Nasdaq:INOD) today released the first stage of its AI Cyber Training Suite - twelve datasets and evaluation systems that train AI coding agents to write code that avoids known security flaws, to avoid introducing new ones, and to patch existing vulnerabilities in the software companies already run. The suite addresses what has become a central barrier to trusting AI-written code: the risk that an agent, while adding a feature or modernizing a legacy system, quietly opens a security hole. The AI Cyber Training Suite works across the stack of coding agents - the models, the harnesses, and the tools - to help ensure the code they produce is not just functional, but secure. It is available to model builders and enterprise
Ore Energy Raises $43 Million to Unlock Renewable Baseload Power for the AI Era4.8.2026 09:00:00 CEST | Press release
Ore Energy is building a fully European-manufactured battery to solve one of the biggest bottlenecks in the energy transition: multi-day storage Europe already wastes an estimated 72 TWh of renewable energy due to grid bottlenecks, equivalent to Austria's annual electricity demand, with losses projected to rise to as much as 410 TWh annually by 2040, according to the European Commission's Joint Research Centre Its iron-air batteries store power for 100 hours at 10x lower cost per unit of energy capacity than lithium-ion, without the need for critical raw minerals like lithium or cobalt AMSTERDAM, NL AND DELFT, NL / ACCESS Newswire / August 4, 2026 / As demand for electricity from AI, manufacturing, and the energy transition accelerates worldwide, Ore Energy has raised $43 million in Series A funding from Plural and HV to scale its iron-air battery technology. Ore's batteries, designed to store renewable electricity for up to 100 hours, can solve one of the biggest barriers to the energ
Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination1.8.2026 01:15:00 CEST | Press release
Strategic Transaction to Position Thunder Bay North for Development, Strengthen Capital Markets Profile and Create a New Critical Minerals Growth Platform Not for distribution to United States newswire services or for dissemination in the United States. Highlights A strategic business combination with Springbok Ventures, a Fiore Group-backed company focused on critical minerals in Ontario Creation of a growth-oriented critical minerals platform focused on domestic critical minerals in Canada with the ability to pursue future acquisitions and strategic opportunities Minimum C$5 million concurrent financing of subscription receipts Partnership with the Fiore Group, one of Canada's leading mining groups Continued advancement of the Thunder Bay North Critical Minerals Project Addition of the Maude Lake Property in Ontario as an exploration asset THUNDER BAY, ON / ACCESS Newswire / July 31, 2026 / Clean Air Metals Inc. ("Clean Air Metals") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF), 1602037 B.C. Ltd.
Review of 31 Studies Finds Vegan Dog Food and Vegan Cat Food Are Well Digested30.7.2026 21:00:00 CEST | Press release
LONDON, UK / ACCESS Newswire / July 30, 2026 / A new scientific review has found that nutritionally sound vegan dog food, vegan cat food and vegetarian pet diets are generally well digested and broadly comparable to conventional meat-based diets. The review, published in the journal Animals, examined 31 existing studies assessing the digestibility of vegan, vegetarian and plant-based pet diets and ingredients in dogs and cats. Twenty-two studies focused on dogs, two on cats and seven included both species. The review found that across a wide range of study designs, dietary ingredients and digestibility measures, vegan and vegetarian diets consistently showed high digestibility and were not normally significantly less digestible than conventional meat-based diets. Digestibility is an important factor because it indicates how effectively animals can absorb and utilise nutrients from food. While modern commercial plant-based pet foods are generally formulated to provide all essential nutr
Polaris Renewable Energy Announces Q2 2026 Results30.7.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / July 30, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the three and six months ended June 30, 2026. This earnings release should be read in conjunction with the Company's consolidated financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. HIGHLIGHTS Second quarter consolidated energy production totaled 199,130 MWh, representing a 8% decrease from 215,797 MWh in the same quarter last year. The decrease was consistent with management's expectations and primarily reflects higher curtailment in the Dominican Republic and the return to normalized hydrological conditions in Peru and Ecuador. The comparative period benefited from exceptionally strong
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom